AstraZeneca reported on Monday that its COVID-19 vaccine provided strong protection among adults of all ages in a long-anticipated U.S. study
Results from a U.S. trial of AstraZeneca’s COVID-19 vaccine may have used “outdated information,” U.S. federal health officials said in a statement early on March 23.
Also read: U.S. data shows AstraZeneca’s vaccine is effective for all ages
Late on Monday, the Data and Safety Monitoring Board said in a statement that it was concerned that AstraZeneca may have provided an incomplete view of the efficacy data.
AstraZeneca reported on Monday that its COVID-19 vaccine provided strong protection among adults of all ages in a long-anticipated U.S. study, a finding that could help rebuild public confidence in the shot around the world and move it a step closer to clearance in the U.S.
In the study of 30,000 people, the vaccine was 79% effective at preventing symptomatic cases of COVID-19 — including in older adults.
There were no severe…
